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Background: Diagnosis of cancer invasion depth is crucial for selecting the optimal treatment strategy in patients with
gastrointestinal cancers. We conducted a meta-analysis to determine the utilities of different endoscopic modalities for
diagnosing invasion depth of esophageal squamous cell carcinoma (SCC).
Methods: We conducted a comprehensive search of MEDLINE, Cochrane Central, and Ichushi databases to identify
studies evaluating the use of endoscopic modalities for diagnosing invasion depth of superficial esophageal SCC. We
excluded case reports, review articles, and studies in which the total number of patients or lesions was <10.
Results: Fourteen studies fulfilled our criteria. Summary receiver operating characteristic curves showed that magnified
endoscopy (ME) and endoscopic ultrasonography (EUS) performed better than non-ME. ME was associated with high
sensitivity and a very low (0.08) negative likelihood ratio (NLR), while EUS had high specificity and a very high (17.6)
positive likelihood ratio (PLR) for the diagnosis of epithelial or lamina propria cancers. NLR <0.1 provided strong
evidence to rule out disease, and PLR >10 provided strong evidence of a positive diagnosis.
Conclusions: EUS and ME perform better than non-ME for diagnosing invasion depth in SCC. ME has a low NLR and is
a reliable modality for confirming deep invasion of cancer, while EUS has a high PLR and can reliably confirm that the
cancer is limited to the surface. Effective use of these two modalities should be considered in patients with SCC.
Trial registration: PROSPERO (International Prospective Register of Systematic Reviews); number 42015024462.
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cell carcinomaBackground
Esophageal squamous cell carcinoma (SCC) is one of the
common causes of cancer-related mortality worldwide
[1]. Although the overall survival of patients with
esophageal SCC remains poor, it can potentially be cured
by esophagectomy, endoscopic resection (ER) or chemo-
radiotherapy if diagnosed at an early stage [2–7]. Esoph-
agectomy has been the mainstay of treatment for
superficial esophageal SCC. However, this procedure is* Correspondence: isihara-ry@mc.pref.osaka.jp
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and is associated with significant mortality and substan-
tial morbidity [8, 9]. Endoscopic therapy offers an alter-
native, minimally invasive option for patients with
superficial esophageal SCC. Although both these treat-
ments are applicable for superficial esophageal SCC, they
differ greatly in terms of their invasiveness.
Many factors, e.g. the patient’s condition, metastatic
status, cancer invasion depth, and size of the lesion,
must be taken into account when choosing the appropri-
ate treatment. Among these factors, cancer invasion
depth correlates well with the risk of metastasis and the
curability by ER [10, 11]. Diagnosis of cancer invasionle is distributed under the terms of the Creative Commons Attribution 4.0
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ment strategy in patients with esophageal SCC.
Many modalities, e.g. non-magnified endoscopy (non-
ME), magnified endoscopy (ME), and endoscopic ultra-
sound (EUS) are currently used for diagnosing the invasion
depth of superficial esophageal SCC. Non-ME is a conven-
tional diagnostic modality for invasion depth, and the diag-
nosis is usually based on the protrusion, depression,
thickness, and hardness of the esophageal wall. However,
diagnosis by non-ME is subjective and may be subject to
inter-observer variability. ME allows clear observation of
the microvascular architecture, which is closely associated
with the development of esophageal cancer. Diagnosis of
esophageal cancer invasion depth using ME was intro-
duced in the 1990s [12, 13]. This modality requires image-
enhancement and magnifying functions, but can lead to a
rapid and objective diagnosis. EUS is the most popular of
the three modalities, but has produced conflicting results
[14, 15] regarding its utility for diagnosing superficial
esophageal SCC. There is thus currently no consensus on
the best modality for diagnosing invasion depth in patients
with superficial esophageal SCC. We therefore conducted
a meta-analysis to elucidate the utilities of these modalities
for the diagnosis of esophageal cancer invasion depth.
Methods
Search strategy
We searched the MEDLINE, Cochrane Central, and
Ichushi databases from January 1995 to June 2015 using
the following search terms: (“esophageal cancer” OR
“esophageal tumor” OR “esophageal tumor” OR “esopha-
geal neoplasia” OR “esophageal carcinoma” OR “esopha-
geal mucosal” OR “esophageal lamina propria”) AND
(“diagnosis” OR “endosonography” OR “staining and la-
beling” OR “iodine” OR “magnifying endoscopy OR
“chromoendoscopy” OR “NBI” OR “avascular area” OR
“endoscopic ultrasound” OR “imaging” OR “pathology”
OR “esophagoscopy”) AND (“neoplasm invasiveness”
OR “[T1a and EP]” OR “M1” OR “Tis” OR “[T1a and
LPM]” OR “M2” OR “T1a” OR “(T1a and MM)” OR
“M3” OR “T1b” OR “[pT1a and MM]” OR “T1b” OR
“SM” OR “SM1” OR “SM2” OR “SM3” OR “[T1b and
SM] OR “vascular involvement” OR invasion OR “infil-
tration” OR “depth”). Our search was restricted to Eng-
lish- or Japanese-language studies of human subjects.
Two reviewers (R.I. and N.M.) independently screened
the titles and abstracts of all the articles according to the
defined inclusion and exclusion criteria. The final
complete report of all selected articles was then retrieved
and reviewed by the same two reviewers (R.I. and N.M.).
We also manually screened the reference lists of the
selected articles for any potential related articles that
were not identified by the initial search (Manual search-
ing). Discrepancies were resolved by discussions. Theprotocol for this meta-analysis was registered in PROS-
PERO (International Prospective Register of Systematic
Reviews; number 42015024462), in accordance with the
most recently published guidelines [16].
Inclusion and exclusion criteria
The study population consisted of patients with esopha-
geal SCC based on endoscopic biopsy and endoscopic
examination. The intervention was endoscopic diagnosis
(non-ME, ME or EUS) of cancer invasion depth for
superficial SCC. The reference standard was histologic
diagnosis of cancer invasion depth by ER, or from surgi-
cally resected specimens. Acceptable study designs were
retrospective or prospective studies with sufficient data
to allow reconstruction of a diagnostic 2 × 2 table (true
positive, false positive, true negative, and false negative).
We excluded case reports, review articles, and studies in
which the total number of patients or lesions was <10. We
also excluded studies that did not provide any predefined
criteria to diagnose invasion depth and studies with im-
aging modalities that are not used in daily practice.
Cancer invasion depth
Histologic diagnosis of cancer invasion depth was di-
vided into six categories, based on the findings: EP (can-
cer limited to the epithelium); LPM (cancer invading
into the lamina propria); MM (cancer invading into the
muscularis mucosa); SM1 (cancer invading 0.2 mm
below the lower border of the muscularis mucosa in
endoscopically resected specimens and cancer invading
the upper third of the submucosal layer in surgically
resected specimens); SM2 (cancer invading >0.2 mm
into the submucosa in endoscopically resected speci-
mens and cancer invading the middle third of the sub-
mucosal layer in surgically resected specimens); SM3
(cancer invading the lower third of the submucosal layer
in surgically resected specimens) [17].
Endoscopic diagnosis of cancer invasion depth was di-
vided into three categories: EP/LPM, MM/SM1, and ≥
SM2, because these categories correspond well with the
risk of metastasis [10] and indication of ER. Moreover,
most diagnostic criteria for cancer invasion depth of
esophageal SCC were developed to differentiate these
three categories, and there are currently no popular
non-ME or ME criteria for differentiating between mu-
cosal and submucosal cancers.
Data abstraction
Two independent reviewers (R.I. and N.M) extracted the
following data from the selected studies and added them
to standardized data forms: design; country; year of pub-
lication; setting; sample size; reference standard; operat-
ing frequencies of endoscope and/or probe; number of
endoscopic imaging modalities used; and numbers of
Fig. 1 Flow diagram of the study-selection process
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negative values.
Study quality and potential bias were assessed accord-
ing to the Quality Assessment of Diagnostic Accuracy
Studies-2 (QUADAS-2) tool [18], which included four
key domains: patient selection, index test, reference
standard, and flow timing. Each domain was assessed for
risk of bias, and the first three domains were also
assessed regarding applicability. Quality assessment of
the studies was performed independently by R.I. and
N.M, and any disagreement was resolved by discussion.
Statistical analysis
We constructed 2 × 2 tables for EP/LPM and ≥MM, and
for EP-SM1 and ≥ SM2 for each study, based on compari-
sons between the endoscopic diagnosis and final histologic
diagnosis by ER or esophagectomy. The true-positive, false-
positive, true-negative, and false-negative values were then
calculated based on the 2 × 2 tables. A summary receiver
operating characteristic curve (SROC) was constructed
[19]. A SROC is similar to a standard ROC, except that the
SROC data are obtained from the sensitivity and specificity
values in the individual studies in the meta-analysis. The
area under the curve (AUC) of a SROC is an indicator of
the performance of a diagnostic modality [19]. A preferred
test has an AUC close to 1, and a poor test has an AUC
close to 0.5 [20]. The Q* index is the point where the sensi-
tivity and specificity are equal, which is the point closest to
the ideal top-left corner of the SROC space [19].
The pooled sensitivity, specificity, PLR, NLR, and diag-
nostic odds ratio were estimated using a fixed-effect
model (Mantel–Haenszel method). Forest plots were used
to show the effect size of each study. Heterogeneity was
assessed using Cochran’s Q test and the I2 measure of in-
consistency [21–23]. The Cochran Q test detects hetero-
geneity by testing the null hypothesis that all studies in a
meta-analysis have the same underlying magnitude of ef-
fect. Because this test is underpowered to detect moderate
degrees of heterogeneity, a P value of <0.10 was consid-
ered suggestive of significant heterogeneity [24]. The I2
index describes the percentage of total variation among
studies attributed to heterogeneity rather than chance. A
value of 0% indicates no observed heterogeneity, and lar-
ger values show increasing heterogeneity. Higgins et al.
[21] suggested that I2 indexes of 25%, 50%, and 75% repre-
sented low, moderate, and high heterogeneity, respect-
ively. For all statistical methods, except for Cochran’s Q
test, P <0.05 was regarded as significant. Data were ana-
lyzed using Meta-Disc (version 1.4) and Review Manager.
Results
Literature search
A total of 359 articles were initially identified using the
search strategy, and 18 additional records were identifiedthrough manual searching of references (Fig. 1). Among
all the studies, 300 were excluded after preliminary re-
view of the titles and abstracts, leaving 77 articles for de-
tailed evaluation. Of these, 63 articles failed to meet the
criteria and 14 studies were finally selected for this
meta-analysis [25–38]. Only two of these were prospect-
ively designed studies [27, 36]. All of 14 were Japanese
studies and 11 of them were written in Japanese. A total
of 359, 1613 and 357 patients received non-ME, ME and
EUS, respectively. Details of the studies are described in
Table 1 [12, 13, 39].
Meta-analysis of diagnostic accuracy
Summary ROC curves showed that ME and EUS were
positioned in the upper right corner of the ROC space
compared with non-ME (Fig. 2a, b). The AUC was used
to summarize the overall diagnostic accuracy of each
modality. Non-ME, ME, and EUS had AUC values of
0.934, 0.946, and 0.975, respectively, for differentiating
between EP/LPM and ≥MM, while ME and EUS had
AUC values of 0.999 and 0.966, respectively, for differen-
tiating between EP-SM1 and ≥ SM2.
The Forest plots of sensitivity, specificity, PLR, and NLR
for each modality for differentiating between EP/LPM
and ≥MM, and between EP-SM1 and ≥ SM2 are shown in
Fig. 3a–d and e–h, respectively. Point estimates with 95%
confidence intervals (CIs) were plotted for each group
(Fig. 3 a-h). ME had significantly higher sensitivities for











25 1997 74 Non-ME Non - - - Esophagectomy/
ER
26 2010 236 Non-ME Non - - - Esophagectomy/
ER






28 1998 30 ME Non Arima - - Esophagectomy/
ER
29 2002 79 ME Non Inoue - - Esophagectomy/
ER
30 2006 12 ME Non Inoue - - ER
31 2010 510 ME FICE Arima - - Esophagectomy/
ER
32 2014 220 ME NBI JES - - ER
33 2014 249 ME NBI JES - - ER
34 2014 464 ME NBI JES - - Esophagectomy/
ER




36 2006 40 EUS - - Mini-probe 20 Esophagectomy/
ER




38 2011 145 EUS - - Mini-probe 20,30 Esophagectomy/
ER
Non-ME non-magnified endoscopy; ME magnified endoscopy; EUS endoscopic ultrasound; IE Image enhancement method; FICE FUJI Intelligent Color Enhancement
system; NBI Narrow band imaging system; Arima Arima’s classification; Inoue Inoue’s classification; JES Japan esophageal society classification; ER endoscopic
resection
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cancers (1.00 [95%CI: 0.99–1.00]) compared with non-ME
and EUS. ME also had very low NLR for diagnosing EP/
LPM (0.08 [95%CI: 0.03–0.25]) and EP-SM1 cancers (0.01
[95%CI: 0.00–0.02]). EUS showed significantly higher spec-
ificities for the diagnosis of EP/LPM (0.97 [95%CI: 0.93–
0.99]) and EP-SM1 cancers (0.94 [95%CI: 0.98–0.88])Fig. 2 Summary receiver operating characteristic curves for differentiatin
epithelium, LPM: lamina propria, MM: muscularis mucosa, SM: submuco
non-magnified endoscopycompared with non-ME and ME. EUS also had a very high
PLR for diagnosing EP/LPM (17.63 [95%CI: 6.71–46.34])
and EP-SM1 cancers (11.60 [95%CI: 5.44–24.74]).
Quality and heterogeneity assessment
The qualities of the included studies evaluated according
to the QUADAS-2 criteria are shown in Fig. 4. Half theg between EP/LPM and ≥MM (a), and EP-SM1 and ≥ SM2 (b). EP:
sa, EUS: endoscopic ultrasound, ME: magnified endoscopy, Non-ME:
Fig. 3 a Sensitivity for differentiating between EP/LPM and≥MM. b Specificity for differentiating between EP/LPM and≥MM. c Positive likelihood ratio
for differentiating between EP/LPM and≥MM. d Negative likelihood ratio for differentiating between EP/LPM and≥MM. e Sensitivity for differentiating
between EP-SM1 and≥ SM2. f Specificity for differentiating between EP-SM1 and≥ SM2. g Positive likelihood ratio for differentiating between EP-SM1
and≥ SM2. h Negative likelihood ratio for differentiating between EP-SM1 and≥ SM2. EP: epithelium, LPM: lamina propria, MM: muscularis mucosa, SM:
submucosa, EUS: endoscopic ultrasound, ME: magnified endoscopy, Non-ME: non-magnified endoscopy
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and “Flow and timing”, mainly as a result of unclear de-
scriptions of the patient-selection process and analysis
methods. The Cochran Q test identified heterogeneities
for differentiating between EP/LPM and ≥MM by non-
ME (P = 0.076 for sensitivity and P = 0.002 for specificity)
and ME (P = 0.002 for sensitivity and P < 0.001 for speci-
ficity), between EP-SM1 and ≥ SM2 by ME (P < 0.001 for
specificity). The I2 index identified moderate to high het-
erogeneities for differentiating between EP/LPM and ≥MM by non-ME (61.2% for sensitivity and 83.5% for spe-
cificity) and ME (91.3% for sensitivity and 87.7% for spe-
cificity), between EP-SM1 and ≥ SM2 by ME (91.2% for
specificity). Sensitivity analysis was not performed be-
cause of the limited number of studies of each modality.
However, heterogeneity for differentiating between EP/
LPM and ≥MM by non-ME was resolved by excluding
one study [27], and heterogeneity for differentiating be-
tween EP-SM1 and ≥ SM2 by ME was resolved by ex-
cluding another study [31].
Fig. 4 Quality of the included studies evaluated according to the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria. EP:
epithelium, LPM: lamina propria, MM: muscularis mucosa, SM: submucosa
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The current meta-analysis analyzed the performances of
non-ME, ME, and EUS for diagnosing superficial esopha-
geal SCC. SROCs showed a trade-off between sensitivity
and specificity. Given that an AUC of 1 indicated an excel-
lent test, EUS and ME demonstrated very high diagnostic
accuracies. EUS and ME had different characteristics ac-
cording to our analysis. ME showed high sensitivities for
the diagnosis of EP/LPM and EP-SM1 cancers and very
low NLRs for the diagnosis of EP/LPM and EP-SM1 can-
cers. The NLR assesses the ability of the test to exclude
the disease in question. An NLR <0.1 provides strong evi-
dence to rule out the disease [40], indicating that ME is a
reliable modality for confirming deep cancer invasion.
EUS had high specificities and very high PLRs for the
diagnosis of EP/LPM and EP-SM1 cancers. The PLR is a
measure of how well the test identified the disease. A PLR
>10 provides strong evidence for a positive diagnosis [40],
and indicated that EUS was a reliable modality for con-
firming that the cancer was limited to the surface. Effect-
ive use of these two modalities to investigate these
characteristics in clinical practice is important.
Although the current meta-analysis analyzed the diag-
nostic abilities of the individual modalities, they are usu-
ally used in combination in clinical practice. Non-ME is
conducted as an initial examination in most cases, usu-
ally followed by EUS, ME, or both. However, there are
currently no guidelines or consensus on how best to
combine these modalities, and further studies are there-
fore needed to clarify the additional benefits of combina-
tions of these modalities.All the selected articles in the current study were re-
ported from Japan and 11 of them were written in Japa-
nese. This is probably because we limited the disease to
SCC, and the cancer invasion depth categories to EP/
LPM, MM/SM1 and ≥ SM2. This is one of the limita-
tions of this meta-analysis and may raise some concern
about generalizability of the result. This point should be
confirmed by further studies outside Japan.
Classification of the invasion depth of superficial
esophageal SCCs into three categories (EP/LPM, MM/
SM1, and ≥ SM2) is relatively uncommon, but neverthe-
less practical. It can stratify the risk of metastasis [10],
and is therefore closely associated with the indication for
ER. According to the Japanese [41] and European [11]
guidelines, ER is indicated for EP/LPM cancer, relatively
indicated for MM/SM1 cancer, and not indicated for ≥
SM2 cancer. We therefore employed these categories in
this meta-analysis.
There were some limitations of this meta-analysis.
Non-ME and ME demonstrated heterogeneity for differ-
entiating between EP/LPM and ≥MM, and ME for dif-
ferentiating between EP-SM1 and ≥ SM2. We were
unable to perform sensitivity analyses because of the
limited number of studies for each modality. However,
heterogeneities for differentiating between EP/LPM
and ≥MM by non-ME [27], and between EP-SM1 and ≥
SM2 by ME were resolved by excluding one study each
[31]. Most of the articles in this meta-analysis were re-
ported from university hospitals or tertiary care hospi-
tals, which specialize in cancer treatment. However, the
two studies excluded above were unique; the former was
Ishihara et al. BMC Gastroenterology  (2017) 17:24 Page 7 of 8conducted in secondary care general hospitals, and the
latter was conducted by one investigator with special ex-
pertise in the diagnosis of esophageal SCC [31]. Another
limitation of this meta-analysis was the low quality of
the studies evaluated by QUADAS-2. Half of the
studies had issues of bias regarding “Patient selection”
and “Flow and timing”, which may have derived from
the patient-selection and analysis processes. These
problems cannot be resolved by a retrospective study
style, and well-designed prospective studies are re-
quired to allow a better meta-analysis to be per-
formed to provide stronger evidence.
Conclusion
EUS and ME are preferable to non-ME for diagnosing
invasion depth in esophageal SCC. ME demonstrated
very low NLR, and is thus a reliable modality for con-
firming deep cancer invasion, while EUS showed a high
PLR, and is thus a suitable modality for confirming that
a cancer is limited to the surface. Combined use of these
two modalities should thus be considered for determining
cancer invasion depth in patients with esophageal SCC.
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